4月29日 - ** 癌症检测服务公司NeoGenomicsNEO.O的股价盘前下跌3.6%，至9.61美元。
** (link) 根据LSEG汇编的数据，该公司第一季度营收为1.68亿美元，低于分析师预计的1.71亿美元。
** 但该公司将全年营收预期从之前的 7.35 亿至 7.45 亿美元上调至 7.47 亿至 7.59 亿美元。
** 另外，该公司表示 (link)，它正在与生物技术公司Ultima Genomics合作，利用Ultima专为大规模基因组研究设计的测序平台，扩大为癌症患者提供的临床测试服务。
** 截至上次收盘，NEO年累计下跌39.5%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.